Enhancing the photodynamic effect of hypericin in tumour spheroids by fractionated light delivery in combination with hyperoxygenation.
The aim of this study was to explore the hypothesis of oxygen depletion during light irradiation as a possible explanation for the incomplete response seen after hypericin-mediated photodynamic therapy (PDT) under specific conditions. To investigate this, we performed PDT experiments using transitional cell carcinoma spheroids with fractionated light irradiation and hyperoxygenation. After 2-h incubation with 3 different hypericin concentrations, spheroids were irradiated either continuously or with fractionated light delivery. The effect of hyperoxygenation was investigated by bubbling normobaric oxygen in the solution surrounding the spheroids before continuous irradiation or during the dark interval of light fractionation. The PDT efficacy was evaluated with an MTT antiproliferation assay and apoptotic cells were visualized after PDT by DAPI staining. Our results show that fractionated light delivery with dark intervals ranging from 1 to 10 min does not enhance the PDT efficacy in spheroids at all, whereas hyperoxygenation, using appropriate hypericin concentrations and oxygenation intervals, results in a virtually complete malignant cell killing through apoptosis. This study suggests that oxygen depletion is the major source of relative treatment failure in hypericin-mediated PDT with spheroids, which can only be overcome with hyperoxygenation. Therefore, whole bladder wall PDT with hypericin is likely to become a very efficient antitumoural treatment against superficial bladder cancer, on the condition that instillation fluids are hyperoxygenated during light irradiation.
Huygens
Ann
A
Laboratorium voor Farmaceutische Biologie en Fytofarmacologie, Faculteit Farmaceutische Wetenschappen, Belgium.
Kamuhabwa
Appolinary R
AR
Van Laethem
An
A
Roskams
Tania
T
Van Cleynenbreugel
Ben
B
Van Poppel
Hendrik
H
Agostinis
Patrizia
P
De Witte
Peter A M
PA
D000873:Anthracenes; D017209:Apoptosis; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D005453:Fluorescence; D006801:Humans; D008027:Light; D010100:Oxygen / Q000494:pharmacology*; D010569:Perylene / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010778:Photochemotherapy / Q000379:methods*; D018874:Spheroids, Cellular; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000873:Anthracenes; D010569:Perylene; C004965:hypericin; D010100:Oxygen